Search PubMed⌕ Search

Biomedical subjects

B Audhuy

Publications and source records attributed to B Audhuy.

44 records · Page 3Linked to original sources
PubMed1982

[Auer bodies and Ph1 chromosome: chronic myeloid pseudoleukemia?].

In 4 cases, the probable diagnosis was that of a chronic myeloid leukaemia (CML) in a blast crisis, because of the sudden acute onset and the presence of the Ph 1 chromosome. In each case, however, there were Auer bodies in the blasts, an unusual finding in CML. Cytological and cytochemical examination led respectively to the diagnosis of an M2 acute myeloblastic leukaemia (AML), according to the FAB classification, to that of a pre-leukaemia progressing to an M2 AML, to that of a M3 promyelocyte leukaemia, with numerous monocytes and finally, in one case, the diagnosis lay between a possible acute crisis of CML with Auer bodies or an acute myelo-monocyte leukaemia. These atypical findings did not conform to the classic picture of CML and cannot be classified as such in spite of the presence of the Ph 1 chromosome. To consider them as true CML would be to run a risk of distorting the haematological evolutive and therapeutic aspects of this disease.

Adult↗
PubMed1981

[Juvenile diabetes of recent onset. Sustained insulin remission by means of preprogrammed insulin infusion (author's transl)].

Seven young insulin-dependent diabetic patients were treated within 45 days at the latest from the onset of the disease by programmed insulin infusions delivered with an insulin pump. In every case normal serum glucose levels were obtained. At the end of each 84-hour infusion, an attempt was made to institute oral antidiabetic treatment. This was successful in 6 patients after 2 or 3 infusions and in one patient after 3 infusions followed by 2 months' conventional insulin therapy and a 4th infusion. In 5 patients (71%), oral treatment could be continued for more than 3 months, which indicates sustained remission of insulin-dependence. These results are comparable to those achieved with an artificial pancreas and can be explained by optimal diabetes control during the programmed infusions. The method has the advantages of being simple and relatively inexpensive.

Administration, Oral↗
PubMed1981

[Benoxaprofene: pharmacokinetic profile in the normal subject and patients with renal insufficiency; evaluation of anticipated serum levels].

The pharmacokinetic profile of benoxaprofene, administered in a single oral dose of 600 mg, has been determined comparatively in 5 normal subjects and 15 patients with renal insufficiency (five of whom were on chronic hemodialysis). In the normal subject, the half-absorption time (Ka) was 0.63 hours; a mean theoretical maximal concentration of 47.3 micrograms/ml was reached 3.6 hours after administration of the drug. The decrease in serum levels was particularly slow, the coefficient of total elimination (Ke) being 0.0241(h-1) and the biological half-life attaining 28.8 hours. :The total clearance (Ct = 4.8 ml/min/1.73 m2) and renal clearance (Cr =1.6 ml/min/1.73 m2) values were low. 13.9% of the ingested dose of benoxaprofene was recovered in the 24 hours urinary volume. Renal insufficiency does not significantly change the pharmacokinetic parameters. It appears advisable to reduce the dosage by half only in patients with a Cr clearance of less than 10-20 ml/min/1.73 m2. The theoretical serum values reached after administration of 600 mg benoxaprofene repeated every 6-12-24-36 or 48 hours have been calculated and it has been found that effective concentrations can be obtained by administration of 600 mg every 12 or 24 hours.

Administration, Oral↗
PubMedDate not supplied

[Value of a LHRH agonist (Zoladex) in hormonotherapy of advanced cancers of the prostate. Apropos of 22 patients].

Twenty-two patients with metastatic cancer of the prostate were treated with ZoladexR, an LHRH analogue. In all cases plasma testosterone levels decreased to post-surgical castration values. This inhibitory effect of Zoladex on testicular steroid production had a favourable influence on the course of the malignancy, since 75 p. 100 of objective responses were obtained after 3 months of treatment. The functional symptoms were distinctly improved, and the drug was well tolerated, notably by the cardiovascular system. This immediate effectiveness seemed to last for several months, one-half of the patients still being in remission after 3 to 15 months. The beneficial effects of LHRH agonists, similar to those of pulpectomy or oestrogen therapy, are limited by the susceptibility of the tumour to hormones. In view of their effectiveness and good tolerance, LHRH agonists are useful in the management of advanced prostatic cancer, either as initial therapy or to replace a poorly tolerated oestrogen therapy. Further studies are needed to clarify their indications and the possible value of their association with anti-androgens or antimitotic drugs.

Aged↗
PubMedDate not supplied

[Extraskeletal plasma cell tumors (author's transl)].

Extraskeletal plasmacytomas are very rare malignant plasma cell tumors. They often seem to arise from a pathologic plasma cell reaction to an antigenic stimulation and are characterized by the variety of their locations and the frequent absence of monoclonal dysproteinemia. The authors are reporting three new observations of extraskeletal plasma cell tumors. Some pathological, biological and pathogenic features of these tumors are emphasized.

Aged↗
PubMedDate not supplied

[Immunologically agranulocytosis after ajmaline administration (author's transl)].

The reversible ajmaline induced agranulocytosis is considered as the result of an immunologically mediated destruction. Striking results of leukocyte agglutination test has been observed in the reported case. They suggest that the granulocytic factor involved in this reaction could be in some cases, differentiation membranous antigens. These ones, located on the granulocytic precursors would be detected only during the granulocytic regeneration period.

Aged↗
PubMedDate not supplied

[Importance of disorders of primary hemostasis in the occurrence of upper digestive hemorrhage in cirrhosis].

In order to assess the true incidence of haemostatic disorders in cirrhotic gastro-intestinal haemorrhage, a comparative prospective study of primary haemostasis, coagulation and fibrinolysis was carried out in 37 patients distributed into two groups: cirrhotics with gastro-oesophageal varices that had never bled (Group A = 22), and cirrhotics who had had an intestinal bleed from "ruptured" gastro-oesophageal varices (Group B = 15). Combination of thrombocytopenia (less than 100 10(9)/l) and a bleeding time greater than 8 mn was more frequent in Group B (80%) than in Group A (45%) (p = less than 0.05). On the other hand, no significant difference between the two groups was found in the activated cephalin time, thrombin time, prothrombin complex factors (II, V, VII-X), fibrinogen, antithrombin III, Factor VIII complex factors, FDP levels or plasminogen. In conclusion, these results suggest that disorders of primary haemostasis may be involved in bleeding from gastro-intestinal varices in cirrhosis. However, coagulation disorders and anomalies of fibrinolysis would not seem to play a determining role.

Bleeding Time↗